GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Total Equity

Immuron (STU:ANWA) Total Equity : €10.76 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Immuron Total Equity?

Immuron's total equity for the quarter that ended in Dec. 2023 was €10.76 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Immuron Total Equity Historical Data

The historical data trend for Immuron's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Total Equity Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Equity
Get a 7-Day Free Trial Premium Member Only 4.52 3.46 16.43 15.41 12.15

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.31 15.41 13.55 12.15 10.76

Immuron Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Immuron's Total Equity for the fiscal year that ended in Jun. 2023 is calculated as

Total Equity=Total Assets(Q: Jun. 2023 )-Total Liabilities(Q: Jun. 2023 )
=13.621-1.469
=12.15

Immuron's Total Equity for the quarter that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=12.204-1.446
=10.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immuron Total Equity Related Terms

Thank you for viewing the detailed overview of Immuron's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (STU:ANWA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » Total Equity
Comparable Companies
ASX:NOX ASX:ACR ASX:CHM ASX:1AI ASX:ATX ASX:ATH ASX:PAB ASX:RAD ASX:BTC ASX:1AD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IMRN:USA ANWA:Germany IMC:Australia
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Website
https://www.immuron.com.au
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines